Adrian Krainer, Ph.D.
Cold Spring Harbor Laboratory

Adrian R. Krainer, Ph.D., co-founded Stoke Therapeutics and is the St. Giles Professor and Deputy Director of the Cancer Center at Cold Spring Harbor Laboratory, a biological research institution, where he has served since 1986. His research led directly to the invention and development of SPINRAZA, the first approved drug for spinal muscular atrophy. Dr. Krainer holds a B.A. in Biochemistry from Columbia University and a Ph.D. in Biochemistry from Harvard University. He has extensive experience in RNA splicing and antisense technology. Dr. Krainer is an elected member of the National Academy of Sciences, the National Academy of Medicine and the National Academy of Inventors. He is a recipient of the 2019 Breakthrough Prize in Life Sciences, the 2019 RNA Society Lifetime Achievement Award, the 2019 Zülch Prize in Basic Neurological Research, the 2019 Speiser Award in Pharmaceutical Sciences, and the 2020 Ross Prize in Molecular Medicine. Dr. Krainer serves on Stoke’s Board of Directors and as Chair of the Scientific Advisory Board.